Chinese General Practice ›› 2023, Vol. 26 ›› Issue (08): 911-916.DOI: 10.12114/j.issn.1007-9572.2022.0660
Special Issue: 内分泌代谢性疾病最新文章合辑; 消化系统疾病最新文章合辑
• Original Research • Previous Articles Next Articles
Received:
2022-09-11
Revised:
2022-11-10
Published:
2023-03-15
Online:
2022-11-24
Contact:
DENG Xia, YUAN Guoyue
通讯作者:
邓霞, 袁国跃
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0660
组别 | 例数 | 性别(男/女) | 年龄(岁) | T2DM病程〔M(P25,P75),月〕 | 高血压病史〔n(%)〕 | 吸烟史〔n(%)〕 | 饮酒史〔n(%)〕 | BMI(kg/m2) | WHR〔M(P25,P75)〕 |
---|---|---|---|---|---|---|---|---|---|
非NAFLD组 | 50 | 27/23 | 58.8±12.7 | 120(33,168) | 21(42.0) | 12(24.0) | 9(18.0) | 23.8±3.0 | 0.93(0.88,0.97) |
NAFLD组 | 80 | 47/33 | 53.6±11.8 | 24(1,120) | 35(43.8) | 22(27.5) | 12(15.0) | 25.8±2.9 | 0.94(0.91,0.98) |
检验统计量值 | 0.283b | 2.359 | -3.545a | 0.038b | 0.195b | 0.204b | -3.884 | -1.077a | |
P值 | 0.595 | 0.020 | <0.001 | 0.845 | 0.659 | 0.651 | <0.001 | 0.282 | |
组别 | SBP(mm Hg) | DBP〔M(P25,P75),mm Hg〕 | FPG(mmol/L) | 2 hPG(mmol/L) | FIns〔M(P25,P75),U/ml〕 | 2 hIns〔M(P25,P75),U/ml〕 | FCP(g/L) | 2 hCP〔M(P25,P75),g/L〕 | |
非NAFLD组 | 134±17 | 80(73,86) | 9.94±3.55 | 19.65±5.50 | 4.84(3.17,11.89) | 23.43(13.76,46.83) | 1.93±0.96 | 3.42(2.53,5.31) | |
NAFLD组 | 134±17 | 80(72,90) | 10.26±3.03 | 18.90±4.63 | 8.35(5.18,13.33) | 30.00(17.81,52.99) | 2.66±1.12 | 5.35(3.50,7.63) | |
检验统计量值 | 0.089 | -0.062a | -0.540 | 0.837 | -2.508a | -2.070a | -3.811 | -3.718a | |
P值 | 0.929 | 0.950 | 0.590 | 0.404 | 0.012 | 0.038 | <0.001 | <0.001 | |
组别 | HOMA-IR〔M(P25,P75)〕 | HOMA-β〔M(P25,P75)〕 | HbA1c(%) | TG〔M(P25,P75),mmol/L〕 | TC〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C(mmol/L) | ||
非NAFLD组 | 2.47(1.58,4.21) | 17.22(8.26,49.21) | 9.62±2.13 | 1.56(1.12,2.12) | 4.64(4.23,5.55) | 1.09(0.93,1.31) | 2.85±0.80 | ||
NAFLD组 | 3.64(2.56,4.98) | 26.86(14.98,45.50) | 9.50±2.03 | 2.24(1.51,3.72) | 4.83(4.14,6.01) | 1.06(0.87,1.23) | 2.91±0.84 | ||
检验统计量值 | -2.852a | -1.847a | 0.316 | -3.759a | -0.658a | -1.146a | -0.416 | ||
P值 | 0.004 | 0.065 | 0.929 | <0.010 | 0.511 | 0.252 | 0.678 | ||
组别 | ALT〔M(P25,P75),U/L〕 | AST〔M(P25,P75),U/L〕 | SUA(μmol/L) | Scr〔M(P25,P75),mol/L〕 | BUN〔M(P25,P75),mmol/L〕 | EDA〔M(P25,P75),ng/L〕 | |||
非NAFLD组 | 15.10(10.03,22.00) | 14.30(12.10,19.65) | 273.07±89.84 | 58.10(50.00,72.98) | 5.50(4.49,6.62) | 309.13(235.39,402.56) | |||
NAFLD组 | 27.45(14.30,43.43) | 19.75(13.50,29.10) | 314.05±88.76 | 58.60(51.25,68.65) | 4.95(4.28,5.72) | 363.17(312.50,437.17) | |||
检验统计量值 | -3.963a | -2.759a | -2.549 | -0.502a | -2.393a | -2.859a | |||
P值 | <0.010 | 0.006 | 0.012 | 0.615 | 0.017 | 0.004 |
Table 1 Comparison of baseline data between T2DM patients with and without ultrasound-detected NAFLD
组别 | 例数 | 性别(男/女) | 年龄(岁) | T2DM病程〔M(P25,P75),月〕 | 高血压病史〔n(%)〕 | 吸烟史〔n(%)〕 | 饮酒史〔n(%)〕 | BMI(kg/m2) | WHR〔M(P25,P75)〕 |
---|---|---|---|---|---|---|---|---|---|
非NAFLD组 | 50 | 27/23 | 58.8±12.7 | 120(33,168) | 21(42.0) | 12(24.0) | 9(18.0) | 23.8±3.0 | 0.93(0.88,0.97) |
NAFLD组 | 80 | 47/33 | 53.6±11.8 | 24(1,120) | 35(43.8) | 22(27.5) | 12(15.0) | 25.8±2.9 | 0.94(0.91,0.98) |
检验统计量值 | 0.283b | 2.359 | -3.545a | 0.038b | 0.195b | 0.204b | -3.884 | -1.077a | |
P值 | 0.595 | 0.020 | <0.001 | 0.845 | 0.659 | 0.651 | <0.001 | 0.282 | |
组别 | SBP(mm Hg) | DBP〔M(P25,P75),mm Hg〕 | FPG(mmol/L) | 2 hPG(mmol/L) | FIns〔M(P25,P75),U/ml〕 | 2 hIns〔M(P25,P75),U/ml〕 | FCP(g/L) | 2 hCP〔M(P25,P75),g/L〕 | |
非NAFLD组 | 134±17 | 80(73,86) | 9.94±3.55 | 19.65±5.50 | 4.84(3.17,11.89) | 23.43(13.76,46.83) | 1.93±0.96 | 3.42(2.53,5.31) | |
NAFLD组 | 134±17 | 80(72,90) | 10.26±3.03 | 18.90±4.63 | 8.35(5.18,13.33) | 30.00(17.81,52.99) | 2.66±1.12 | 5.35(3.50,7.63) | |
检验统计量值 | 0.089 | -0.062a | -0.540 | 0.837 | -2.508a | -2.070a | -3.811 | -3.718a | |
P值 | 0.929 | 0.950 | 0.590 | 0.404 | 0.012 | 0.038 | <0.001 | <0.001 | |
组别 | HOMA-IR〔M(P25,P75)〕 | HOMA-β〔M(P25,P75)〕 | HbA1c(%) | TG〔M(P25,P75),mmol/L〕 | TC〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C(mmol/L) | ||
非NAFLD组 | 2.47(1.58,4.21) | 17.22(8.26,49.21) | 9.62±2.13 | 1.56(1.12,2.12) | 4.64(4.23,5.55) | 1.09(0.93,1.31) | 2.85±0.80 | ||
NAFLD组 | 3.64(2.56,4.98) | 26.86(14.98,45.50) | 9.50±2.03 | 2.24(1.51,3.72) | 4.83(4.14,6.01) | 1.06(0.87,1.23) | 2.91±0.84 | ||
检验统计量值 | -2.852a | -1.847a | 0.316 | -3.759a | -0.658a | -1.146a | -0.416 | ||
P值 | 0.004 | 0.065 | 0.929 | <0.010 | 0.511 | 0.252 | 0.678 | ||
组别 | ALT〔M(P25,P75),U/L〕 | AST〔M(P25,P75),U/L〕 | SUA(μmol/L) | Scr〔M(P25,P75),mol/L〕 | BUN〔M(P25,P75),mmol/L〕 | EDA〔M(P25,P75),ng/L〕 | |||
非NAFLD组 | 15.10(10.03,22.00) | 14.30(12.10,19.65) | 273.07±89.84 | 58.10(50.00,72.98) | 5.50(4.49,6.62) | 309.13(235.39,402.56) | |||
NAFLD组 | 27.45(14.30,43.43) | 19.75(13.50,29.10) | 314.05±88.76 | 58.60(51.25,68.65) | 4.95(4.28,5.72) | 363.17(312.50,437.17) | |||
检验统计量值 | -3.963a | -2.759a | -2.549 | -0.502a | -2.393a | -2.859a | |||
P值 | <0.010 | 0.006 | 0.012 | 0.615 | 0.017 | 0.004 |
指标 | 年龄 | BMI | WHR | SBP | DBP | FPG | 2 hPG | FIns | 2 hIns | FCP | 2 hCP | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
r(rs)值 | 0.222 | 0.093 | -0.113a | 0.094 | -0.020a | -0.104 | 0.040 | 0.224a | 0.207a | 0.069 | 0.149a | |
P值 | 0.011 | 0.291 | 0.199 | 0.286 | 0.823 | 0.239 | 0.653 | 0.010 | 0.018 | 0.439 | 0.091 | |
指标 | HOMA-IR | HOMA-β | HbA1c | TG | TC | HDL-C | LDL-C | ALT | AST | SUA | Scr | BUN |
r(rs)值 | 0.210a | 0.173a | 0.017 | 0.038a | 0.116a | 0.089a | 0.089 | 0.158a | 0.251a | 0.103 | 0.187a | 0.029a |
P值 | 0.017 | 0.049 | 0.844 | 0.669 | 0.188 | 0.315 | 0.316 | 0.072 | 0.004 | 0.244 | 0.033 | 0.747 |
Table 2 Correlation analysis of serum ectodysplasin A with clinical and biochemical indices in T2DM patients
指标 | 年龄 | BMI | WHR | SBP | DBP | FPG | 2 hPG | FIns | 2 hIns | FCP | 2 hCP | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
r(rs)值 | 0.222 | 0.093 | -0.113a | 0.094 | -0.020a | -0.104 | 0.040 | 0.224a | 0.207a | 0.069 | 0.149a | |
P值 | 0.011 | 0.291 | 0.199 | 0.286 | 0.823 | 0.239 | 0.653 | 0.010 | 0.018 | 0.439 | 0.091 | |
指标 | HOMA-IR | HOMA-β | HbA1c | TG | TC | HDL-C | LDL-C | ALT | AST | SUA | Scr | BUN |
r(rs)值 | 0.210a | 0.173a | 0.017 | 0.038a | 0.116a | 0.089a | 0.089 | 0.158a | 0.251a | 0.103 | 0.187a | 0.029a |
P值 | 0.017 | 0.049 | 0.844 | 0.669 | 0.188 | 0.315 | 0.316 | 0.072 | 0.004 | 0.244 | 0.033 | 0.747 |
指标 | β | 95%CI | SE | 标准化β | t值 | P值 |
---|---|---|---|---|---|---|
常量 | 502.738 | (203.176,802.300) | 151.361 | — | 3.321 | 0.001 |
年龄 | 1.957 | (0.412,3.502) | 0.781 | 0.214 | 2.506 | 0.013 |
WHR | -328.845 | (-638.903,-18.788) | 156.664 | -0.175 | -2.099 | 0.038 |
2 hIns | 0.523 | (0.036,1.011) | 0.246 | 0.181 | 2.125 | 0.036 |
AST | 2.148 | (0.520,3.776) | 0.823 | 0.220 | 2.611 | 0.010 |
Table 3 Multiple linear regression analysis of factors associated with serum ectodysplasin A in T2DM
指标 | β | 95%CI | SE | 标准化β | t值 | P值 |
---|---|---|---|---|---|---|
常量 | 502.738 | (203.176,802.300) | 151.361 | — | 3.321 | 0.001 |
年龄 | 1.957 | (0.412,3.502) | 0.781 | 0.214 | 2.506 | 0.013 |
WHR | -328.845 | (-638.903,-18.788) | 156.664 | -0.175 | -2.099 | 0.038 |
2 hIns | 0.523 | (0.036,1.011) | 0.246 | 0.181 | 2.125 | 0.036 |
AST | 2.148 | (0.520,3.776) | 0.823 | 0.220 | 2.611 | 0.010 |
变量 | 赋值 |
---|---|
发生NAFLD | 是=1,否=0 |
EDA | 实测值 |
高血压病史 | 有=1,无=0 |
吸烟史 | 有=1,无=0 |
饮酒史 | 有=1,无=0 |
性别 | 男=1,女=2 |
年龄 | 实测值 |
T2DM病程 | 实测值 |
BMI | 实测值 |
WHR | 实测值 |
Table 4 Assignment for influencing factors of NAFLD in T2DM analyzed using multivariate Logistic regression
变量 | 赋值 |
---|---|
发生NAFLD | 是=1,否=0 |
EDA | 实测值 |
高血压病史 | 有=1,无=0 |
吸烟史 | 有=1,无=0 |
饮酒史 | 有=1,无=0 |
性别 | 男=1,女=2 |
年龄 | 实测值 |
T2DM病程 | 实测值 |
BMI | 实测值 |
WHR | 实测值 |
指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
未校正模型 | 0.004 | 0.002 | 5.421 | 0.020 | 1.004 | (1.001,1.008) |
模型1 | 0.005 | 0.002 | 7.436 | 0.006 | 1.005 | (1.001,1.009) |
模型2 | 0.006 | 0.002 | 7.074 | 0.008 | 1.006 | (1.001,1.010) |
模型3 | 0.006 | 0.002 | 7.249 | 0.007 | 1.006 | (1.002,1.010) |
Table 5 Multivariate Logistic regression analysis of factors affecting NAFLD in T2DM patients
指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
未校正模型 | 0.004 | 0.002 | 5.421 | 0.020 | 1.004 | (1.001,1.008) |
模型1 | 0.005 | 0.002 | 7.436 | 0.006 | 1.005 | (1.001,1.009) |
模型2 | 0.006 | 0.002 | 7.074 | 0.008 | 1.006 | (1.001,1.010) |
模型3 | 0.006 | 0.002 | 7.249 | 0.007 | 1.006 | (1.002,1.010) |
[1] |
|
[2] |
|
[3] |
|
[4] |
刘君,杨艳君,韩伟. 尿微量白蛋白与尿肌酐比值对2型糖尿病合并非酒精性脂肪肝的影响[J]. 安徽医药,2021,25(8):1656-1659.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care,2014,37(Suppl 1):S81-90. DOI:10.2337/dc14-s081.
|
[11] |
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订)[J]. 中华内科杂志,2010,49(3):275-278. DOI:10.3760/cma.j.issn.0578-1426.2010.03.029.
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
卢亚男,刘丽俊,李伟. GA/HbA1c比值与2型糖尿病合并非酒精性脂肪肝相关[J]. 基础医学与临床,2020,40(12):1636-1639. DOI:10.16352/j.issn.1001-6325.2020.12.006.
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[1] | XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852. |
[2] | ZHAO Yuqing, WANG Wei, CHEN Liyuan, YOU Huijuan, WEI Ying, WANG Qinglu, YANG Fengying. Liver Macrophage Polarisation: a New Target for Exercise Prevention and Treatment of Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(27): 3456-3465. |
[3] | SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374. |
[4] | LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860. |
[5] | ZHOU Qian, WU Xiaomin, WANG Baohua, YAN Ruohan, YU Miao, WU Jing. Study on Nomogram Prediction Model for Risk of Gastric Cancer [J]. Chinese General Practice, 2025, 28(23): 2870-2877. |
[6] | LIANG Hengmiao, HUANG Sizhe, CHEN Yuting, LIU Ce, WANG Huijun, DU Qingfeng. A Retrospective Analysis of the Association between Serum Uric Acid Levels and Insulin Resistance Degrees in Individuals Undergoing Health Examination [J]. Chinese General Practice, 2025, 28(21): 2635-2642. |
[7] | GUO Shengteng, ZHANG Fenfen, WAN Di, YU Dongmei, WANG Qinghua. Risk Factors for Severe Acute Pancreatitis Complicated with Acute Lung Injury: a Meta-analysis [J]. Chinese General Practice, 2025, 28(20): 2546-2554. |
[8] | LYU Lulu, ZHU Wanjie, XIAO Mingyang, LI Yike, ZHANG Juan. Correlation Analysis of the Circadian Rhythmicity of Blood Pressure with Ox-LDL/β2GPI Complex and Carotid Atherosclerosis in Patients with Essential Hypertension [J]. Chinese General Practice, 2025, 28(18): 2228-2233. |
[9] | HAN Zheng, SUN Meng, FU Fanglin, PAN Yaojia, WANG Weiqiang. A Study on the Relationship between the Triglyceride-Glucose Index and Cardiometabolic Multimorbidity in Individuals Aged 50 and Above [J]. Chinese General Practice, 2025, 28(18): 2278-2284. |
[10] | NI Xuetong, AHEYEERKE Halengbieke, TANG Jianmin, CAO Tengrui, TAO Lixin, ZHENG Deqiang, LI Qiang, HAN Yumei, YANG Xinghua. The Bidirectional Temporal Causal Association Study between Dysglycaemia and Non-alcoholic Fatty Liver Disease: Based on the Beijing Health Management Cohort [J]. Chinese General Practice, 2025, 28(13): 1607-1613. |
[11] | WANG Xiaoyu, FENG Zhenzhen, WANG Jun, GUO Xiaochuan, LI Jiansheng. Risk Factors for Acute Kidney Injury in Acute Respiratory Distress Syndrome: a Systematic Review [J]. Chinese General Practice, 2025, 28(12): 1527-1537. |
[12] | SU Jun, WANG Jiamin, SUN Xiaojie. The Relationship between Health Literacy and Online Health Information Search among Caregivers of Pediatric Oncology Children [J]. Chinese General Practice, 2025, 28(10): 1207-1212. |
[13] | ZENG Jialing, MENG Yan, DENG Tingting, LI Jinhua, ZHAO Ping. The Correlation of Non-alcoholic Fatty Liver Disease with Visceral Fat Area and Thyroid Nodules in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(09): 1072-1083. |
[14] | LIAO Xingyu, TIAN Siyu, CHEN Min. The Disease Burden, Risk Factors and Predictive Analysis of Early-onset Colorectal Cancer of Different Genders between China and the World from 1990 to 2021 [J]. Chinese General Practice, 2025, 28(08): 1004-1011. |
[15] | ZOU Songyan, ZHANG Riyi, LI Xiaodong, MU Yinyu. Analysis of Clinical Characteristics and Risk Factors of Systemic Sclerosis Combined with Sjögren's Syndrome [J]. Chinese General Practice, 2025, 28(06): 737-741. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||